X

Healio

Healio
Role of Allogeneic HSCT Fading in Lymphoma Management

As targeted therapies and novel treatments emerge, allogeneic hematopoietic cell transplantation has taken a backseat to immunotherapy in the treatment of lymphoma.

Healio
07/17/2021
FDA Grants Priority Review to Pacritinib for Myelofibrosis With Severe Thrombocytopenia

The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.

Healio
06/01/2021
VTE Incidence in NSCLC Varies by Treatment Type

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

Healio
05/09/2021
FDA Clears IND Application for CAR-Natural Killer Cell Therapy to Treat B-Cell Malignancies

The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with R/R B-cell malignancies.

Healio
05/03/2021
FDA Grants Breakthrough Therapy Designation to Bemarituzumab for Gastric Cancers

The FDA grants breakthrough therapy designation to bemarituzumab for use with CT as first-line treatment of certain patients with GI cancers, according to the agent’s manufacturer.

Healio
04/20/2021
FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer

The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.

Healio
04/16/2021
Anakinra Shows Promise as Steroid-Sparing Agent for CAR T-Cell Therapy-Related Toxicities

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

Healio
04/05/2021
CAR T-Cell Therapy ‘Extremely Effective’ for Advanced Follicular Lymphoma, Early Data Show

Sixty-five percent of patients with R/R FL had an initial complete response to a single infusion of tisagenlecleucel, according to phase 2 study results presented at TCT Meetings Digital Experience

Healio
02/19/2021
Anti-CD22 CAR T-Cell Therapy A ‘Promising Option’ for Advanced B-Cell Malignancies

An investigational CAR T-cell therapy appears safe and demonstrates antitumor activity among patients with R/R B-cell malignancies, according to results presented at TCT Meetings Digital Experience

Healio
02/17/2021
Higher CAR-T Dose Associated With Longer Remission Among Younger Patients With ALL

Children and young adults with ALL who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

Healio
02/16/2021
Subscribe to Healio

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834